BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...Venture, Abingworth and other undisclosed institutional investors.RA, Vivo lead Kira’s $53.5M series B+ roundCross-border biotech Kira Pharmaceuticals...
...CARMA-0508) ARGX-113 (efgartigimod) Bayer AG CureVac N.V. Boxer Capital EcoR1 Capital Omega Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin Capital Woodline Partners Logos Capital Janus Henderson Investors Atlas Venture Abingworth Kira Pharmaceuticals RA...
BioCentury | Nov 13, 2020
Emerging Company Profile

Kira: overcoming the complexities of complement

...inflammatory and autoimmune diseases that address the mechanistic and PK challenges of targeting the complement pathway. Kira Pharmaceuticals Ltd....
...– Complement C1r C1s –Complement component 1 s subcomponentC3 – Complement 3C5 – Complement 5 Sandi Wong Kira Pharmaceuticals Ltd. University...
BioCentury | Nov 10, 2017
Finance

Building Quan

...so far, in companion diagnostics company Qiagen Suzhou Translational Medicine Co. Ltd. and cancer companies Kira Pharmaceuticals Ltd....
...China dMed Co. Ltd., Shanghai, China Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM), Hong Kong, China Kira Pharmaceuticals Ltd....
Items per page:
1 - 3 of 3
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...Venture, Abingworth and other undisclosed institutional investors.RA, Vivo lead Kira’s $53.5M series B+ roundCross-border biotech Kira Pharmaceuticals...
...CARMA-0508) ARGX-113 (efgartigimod) Bayer AG CureVac N.V. Boxer Capital EcoR1 Capital Omega Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin Capital Woodline Partners Logos Capital Janus Henderson Investors Atlas Venture Abingworth Kira Pharmaceuticals RA...
BioCentury | Nov 13, 2020
Emerging Company Profile

Kira: overcoming the complexities of complement

...inflammatory and autoimmune diseases that address the mechanistic and PK challenges of targeting the complement pathway. Kira Pharmaceuticals Ltd....
...– Complement C1r C1s –Complement component 1 s subcomponentC3 – Complement 3C5 – Complement 5 Sandi Wong Kira Pharmaceuticals Ltd. University...
BioCentury | Nov 10, 2017
Finance

Building Quan

...so far, in companion diagnostics company Qiagen Suzhou Translational Medicine Co. Ltd. and cancer companies Kira Pharmaceuticals Ltd....
...China dMed Co. Ltd., Shanghai, China Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM), Hong Kong, China Kira Pharmaceuticals Ltd....
Items per page:
1 - 3 of 3